• Publication Date: 10/01/2010
  • Author(s):
    Sullivan, Timothy
  • Organization(s):
    Mystic Pharmaceuticals
  • Article Type: Technical Articles
  • Subjects: Devices and Components, Industry Issues and Trends, Nasal Delivery
In a pandemic or bio-terror event, faster production, deployment and delivery for less cost are the mission.

Novel advances in intranasal delivery technologies are broadening the nasal route as a viable solution for systemic delivery of a wide range of drugs, biologics and vaccines.1 Nasal delivery offers compelling advantages including bypass of hepatic first-pass metabolism, reduced nausea, reduced toxicity and rapid onset. In addition, non-invasive nasal delivery systems eliminate the risk of inadvertent needle sticks and the disposal of biohazardous “sharps,” a safety concern of vaccines administered with a syringe. Precision, metered dose, intranasal delivery systems, introduced by device manufacturers such as Mystic Pharmaceuticals, Aptar Group and Optinose, provide the capability for individuals to safely self-administer. This capability to self-administer reduces dependency on trained healthcare personnel, a critical consideration for rapid deployment of therapeutics or vaccines to large populations in crisis situations such as a pandemic or bio-terror event.

Download PDF